HIGH END CELLOMICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

High End Cellomics Market Size and Trends

The high end cellomics market size is expected to reach US$ 7.20 Bn by 2030, from US$ 3.90 Bn in 2023, at a CAGR of 9.1% during the forecast period. High end cellomics involves the study of cells and their properties using advanced techniques like microscopy, flow cytometry, mass spectrometry, etc. It enables the analysis of cellular physiology at the single cell level. The rising incidence of chronic diseases like cancer is driving the market growth.

High End Cellomics Market Trends:

• Convergence with Single-cell Analysis: A major trend shaping the global high end cellomics market is in convergence with single cell research tools. Single cell genomic, proteomic, and metabolomic analyses are being integrated with high content imaging to gain the multidimensional view of individual cells. Companies like NanoString and 10x Genomics offer platforms that combine single cell RNA sequencing or proteomics with spatial mapping. The spatial context provided by cellomics complements omics data for comprehensive analysis. For instance, in December 2022, 10x Genomics, a life sciences company, announced the first commercial shipments of its Xenium platform for in situ analysis. Xenium is the next generation of subcellular-resolution targeted spatial profiling of genes and proteins. The platform consists of an adaptable and user-friendly tool, a wide selection of carefully chosen, high-quality panels that are customizable, and Xenium Explorer, a user-friendly program for interactive data visualization.
• Biopharma Industry Adoption: Pharmaceutical and biotechnology companies are increasingly adopting cellomics tools to enhance drug R&D programs. Many top biopharma companies have invested in building in-house cellomics capabilities and centers for high-throughput assays. Outsourcing to contract research organizations offering cellomics services is also rising. Strong industry demand will likely make biopharma the fastest growing end-use segment during the forecast period. For instance, on October 31, 2023, Altasciences, an integrated drug development solution company, announced the completion of the expansion of a new state-of-the-art laboratory in Columbia, Missouri, U.S. The newly expanded, 8,000-square-foot space includes a vast range of services including ligand binding assays, flow cytometry, biomarker analysis, and cell culture capabilities.
• Cell-based Therapy Development: The application of cellomics in development, manufacturing, and testing of cell therapies is rising. Cellomics aids in the optimization of cell culture protocols and characterization of cell phenotype. Moreover, high content analysis is utilized for product safety and potency testing as per regulatory guidelines. Companies developing CAR T-cell, stem cell, and regenerative therapies are actively adopting cellomics, thus contributing to its market expansion.
• Adoption of AI and Machine Learning: AI and machine learning are positively disrupting the global high end cellomics market. Researchers are applying deep learning algorithms to automate image processing and analysis. Companies like Stilla and PathAI offer machine learning powered software for cytological diagnosis and profiling. Moreover, generative neural networks are being leveraged to predict cell morphology changes and simulate complex cell behavior in-silico. The integration of AI in cellomics workflows will continue during the forecast period.